Mercks Keytruda plus chemotherapy gets European nod as neoadjuvant treatment, then continued as adjuvant monotherapy after surgery for locally advanced or early-stage TNBC

Merck, known as MSD outside the United States and Canada, announced that the European Commission has approved Keytruda, Merck